Login to Your Account



Tokai Adds $23M to Series D, Preps Prostate Drug for Trial

By Trista Morrison


Tuesday, September 20, 2011
Tokai Pharmaceuticals Inc. is expected to announce Tuesday that it has raised $23 million in a Series D follow-on round to fund Phase IIb trials of triple-acting prostate cancer drug galeterone (TOK-001).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription